BioSpace News Archive

Sosei Group Corporation will receive a US$3.75 million milestone payment under the 2019 multi-target Research Collaboration and License Agreement with Genentech, a member of the Roche Group.

Molecure S.A. a clinical stage biotechnology company developing first-in-class small molecule drug candidates that directly modulate unexplored protein and RNA targets to treat multiple incurable diseases announces third quarter results for the period ended 30 September 2023.

Oxford Nanopore Technologies plc and Fabric Genomics announced a new collaboration to develop a scalable software solution for the end-to-end analysis and clinical reporting of rich genomic data.

United Therapeutics Corporation announced that Patrick Poisson, Executive Vice President, Technical Operations, will provide an overview and update on the company’s business during a fireside chat session at the UBS Biopharma Conference 2023 in Miami Beach, Florida.

United Therapeutics Corporation, a public benefit corporation, announced that the first patient has enrolled in the registration-phase TETON PPF study, which will evaluate nebulized Tyvaso® Inhalation Solution in 698 adult patients with progressive pulmonary fibrosis.

Bio-Techne Corporation reported its financial results for the first quarter ended September 30, 2023.

InfuSystem Holdings, Inc., a leading national health care service provider, facilitating outpatient care for durable medical equipment manufacturers and health care providers, announced it will issue third quarter 2023 financial results on Tuesday, November 7, 2023, before the market opens.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced new preclinical data showcasing simultaneous and coordinated pre-transcriptional control of multiple genes co-located in an insulated genomic domain (IGD) by a single epigenomic controller (EC) at the 11th International mRNA Health Conference taking place in Berlin, Germany, October 31 – November 2, 2023.

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock.

EyePoint Pharmaceuticals, Inc., a company committed to developing and commercializing therapeutics to improve the lives of patients with retinal diseases, announced it will host a virtual key opinion leader event on Thursday, November 9, 2023 from 8:00 to 9:00 am ET.